Chemotherapy-induced peripheral neurotoxicity: a critical analysis.
Susanna B. Park,David Goldstein,Arun V. Krishnan,Cindy S.-Y. Lin,Michael Friedlander,James T. Cassidy,Martin Koltzenburg,Matthew C. Kiernan +7 more
TLDR
This review will address the increasing importance and challenge of chemotherapy‐induced neurotoxicity, with a focus on neuropathy associated with the treatment of breast cancer, colorectal cancer, testicular cancer, and hematological cancers.Abstract:
With a 3-fold increase in the number of cancer survivors noted since the 1970s, there are now over 28 million cancer survivors worldwide. Accordingly, there is a heightened awareness of long-term toxicities and the impact on quality of life following treatment in cancer survivors. This review will address the increasing importance and challenge of chemotherapy-induced neurotoxicity, with a focus on neuropathy associated with the treatment of breast cancer, colorectal cancer, testicular cancer, and hematological cancers. An overview of the diagnosis, symptomatology, and pathophysiology of chemotherapy-induced peripheral neuropathy will be provided, with a critical analysis of assessment strategies, neuroprotective approaches, and potential treatments. The review will concentrate on neuropathy associated with taxanes, platinum compounds, vinca alkaloids, thalidomide, and bortezomib, providing clinical information specific to these chemotherapies. CA Cancer J Clin 2013;63:419-437. ©2013 American Cancer Society, Inc.read more
Citations
More filters
Journal ArticleDOI
Reactive Oxygen Species (ROS)-Based Nanomedicine.
Bowen Yang,Yu Chen,Jianlin Shi +2 more
TL;DR: In this article, the intrinsic biochemical properties of reactive oxygen species (ROS) underlie the mechanisms that regulate various physiological functions of living organisms, and they play an essential role in regulating various physiological function.
Journal ArticleDOI
Incidence, prevalence, and predictors of chemotherapy-induced peripheral neuropathy: A systematic review and meta-analysis.
Marta Seretny,Gillian L. Currie,Emily S. Sena,Sabrina Ramnarine,Robin Grant,Malcolm R. Macleod,Leslie A. Colvin,Marie Fallon +7 more
TL;DR: A systematic review of studies reporting the prevalence of Chemotherapy‐induced peripheral neuropathy identified 31 studies with data from 4179 patients and identified a number of genetic and clinical risk factors that require further study.
Journal ArticleDOI
Microbiota: a key orchestrator of cancer therapy.
Soumen Roy,Giorgio Trinchieri +1 more
TL;DR: The evidence for the ability of the microbiota to modulate chemotherapy, radiotherapy and immunotherapy is discussed with a focus on the microbial species involved, their mechanism of action and the possibility of targeting the microbiome to improve anticancer efficacy while preventing toxicity.
Journal ArticleDOI
Mechanisms of Chemotherapy-Induced Peripheral Neuropathy.
Renata Zajączkowska,Magdalena Kocot-Kępska,Wojciech Leppert,Anna Wrzosek,Joanna Mika,Jerzy Wordliczek +5 more
TL;DR: A better understanding of the risk factors and underlying mechanisms of CIPN is needed to develop effective preventive and therapeutic strategies and the neurotoxicity mechanisms of the most common antineoplastic agents are reviewed.
Journal ArticleDOI
Pathophysiology of Chemotherapy-Induced Peripheral Neuropathy
Hana Starobova,Irina Vetter +1 more
TL;DR: This review focusses on the commonly used antineoplastic substances oxaliplatin, cisPlatin, vincristine, docetaxel, and paclitaxel which interfere with the cancer cell cycle—leading to cell death and tumor degradation—and cause severe acute and chronic peripheral neuropathies.
References
More filters
Journal ArticleDOI
The reliability and validity of a modified total neuropathy score-reduced and neuropathic pain severity items when used to measure chemotherapy-induced peripheral neuropathy in patients receiving taxanes and platinums
TL;DR: Clinimetric evidence supports the use of 2 new instruments when monitoring taxane- and platinum-related neuropathy and pain, leading to fewer chemotherapy-induced peripheral neuropathy-related devastating effects on functionality and quality of life.
Journal ArticleDOI
Long‐term neurotoxicity effects of oxaliplatin added to fluorouracil and leucovorin as adjuvant therapy for colon cancer: Results from National Surgical Adjuvant Breast and Bowel Project trials C‐07 and LTS‐01
Kelley M. Kidwell,Greg Yothers,Patricia A. Ganz,Stephanie R. Land,Clifford Y. Ko,Reena S. Cecchini,Jacek A. Kopec,Norman Wolmark +7 more
TL;DR: This is the first long‐term assessment which reports the National Surgical Adjuvant Breast and Bowel Project (NSABP) investigation of whether excess neurotoxicity persists beyond 4 years.
Journal ArticleDOI
Taxane-induced peripheral neuropathy and health-related quality of life in postoperative breast cancer patients undergoing adjuvant chemotherapy: N-SAS BC 02, a randomized clinical trial.
Kojiro Shimozuma,Yasuo Ohashi,Ayano Takeuchi,Toshihiko Aranishi,Satoshi Morita,Katsumasa Kuroi,Shozo Ohsumi,Haruhiko Makino,Noriyuki Katsumata,Masaru Kuranami,Kimito Suemasu,Toru Watanabe,Frederick H. Hausheer +12 more
TL;DR: Patient-reported CIPN was significantly more severe with single-agent adjuvant taxane compared to AC followed by taxane treatment; however, the HRQOL findings support that single- agent taxanetreatment is tolerable.
Journal ArticleDOI
Cisplatin neurotoxicity in the treatment of metastatic germ cell tumour: time course and prognosis
TL;DR: Sural nerve sensory action potentials and conduction velocities were unhelpful and none of the 11 patients treated with 3 cycles of chemotherapy had persisting symptoms, and vibration thresholds showed a significant deterioration during chemotherapy.
Journal ArticleDOI
Retrospective study of the impact of pharmacogenetic variants on paclitaxel toxicity and survival in patients with ovarian cancer
Troels K Bergmann,Henrik Gréen,Charlotte Brasch-Andersen,Charlotte Brasch-Andersen,Mansoor Raza Mirza,Jørn Herrstedt,Berit Hølund,Andreas du Bois,Per Damkier,Werner Vach,Kim Brøsen,Carsten Peterson +11 more
TL;DR: CYP2C8*3 and the ABCB1 SNPs C1236T, G2677T/A, and C3435T were not statistically significantly correlated to overall survival, sensoric neuropathy, and neutropenia in 119 patients treated for ovarian cancer with paclitaxel/carboplatin.
Related Papers (5)
Prevention and Management of Chemotherapy-Induced Peripheral Neuropathy in Survivors of Adult Cancers: American Society of Clinical Oncology Clinical Practice Guideline
Dawn L. Hershman,Christina Lacchetti,Robert H. Dworkin,Ellen M. Lavoie Smith,Jonathan Bleeker,Guido Cavaletti,Cynthia Chauhan,Patrick Gavin,Antoinette Lavino,Maryam B. Lustberg,Judith A. Paice,Bryan P. Schneider,Mary Lou Smith,Thomas J. Smith,Shelby A. Terstriep,Nina D. Wagner-Johnston,Kate Bak,Charles L. Loprinzi +17 more